Firebrick Pharma Limited (ASX:FRE)

Australia flag Australia · Delayed Price · Currency is AUD
0.0530
-0.0070 (-11.67%)
Apr 2, 2026, 3:38 PM AEST
Market Cap13.38M +2.7%
Revenue (ttm)410.70K -63.7%
Net Income-2.45M
EPS-0.01
Shares Out252.48M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume115,848
Average Volume80,789
Open0.0600
Previous Close0.0600
Day's Range0.0530 - 0.0600
52-Week Range0.0500 - 0.0920
Beta1.32
RSI42.07
Earnings DateMay 25, 2026

About Firebrick Pharma

Firebrick Pharma Limited engages in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally. It offers nasal spray PVP-I products for the treatment of common cold. The company was incorporated in 2012 and is based in Melbourne, Australia. [Read more]

Sector Healthcare
Founded 2012
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol FRE
Full Company Profile

Financial Performance

In fiscal year 2025, Firebrick Pharma's revenue was 515,507, a decrease of -81.26% compared to the previous year's 2.75 million. Losses were -2.63 million, 124.0% more than in 2024.

Financial Statements